肠道微生物组构成或可提示临床前阿尔茨海默病
这项横断面研究纳入164名认知正常个体,其中49人具有早期临床前阿尔茨海默病的生物标志物证据。临床前阿尔茨海默病个体的肠道微生物分类谱与无证据者不同,且与β-淀粉样蛋白和tau病理生物标志物相关,而与神经退行性生物标志物无关。
要点
- 临床前阿尔茨海默病个体的肠道微生物分类谱与无证据者存在差异。
- 肠道微生物组构成变化与β-淀粉样蛋白和tau病理生物标志物相关,与神经退行性生物标志物无关。
- 纳入微生物组特征提高了机器学习分类器预测临床前阿尔茨海默病状态的准确性、敏感性和特异性。
核心结论
- 临床前阿尔茨海默病个体的肠道微生物分类谱与无证据者不同,提示肠道微生物组可能在疾病早期发生变化。
研究设计与样本
- 横断面研究,纳入164名认知正常个体,其中49人具有早期临床前阿尔茨海默病的生物标志物证据,分析中考虑了临床协变量和膳食摄入。
主要发现
- 临床前阿尔茨海默病个体的肠道微生物分类谱与无证据者不同。
- 肠道微生物组构成变化与β-淀粉样蛋白和tau病理生物标志物相关,但与神经退行性生物标志物无关。
- 鉴定出与临床前阿尔茨海默病相关的特定肠道细菌分类群。
- 在164名参与者中的65人子集上测试时,纳入这些微生物组特征提高了机器学习分类器预测临床前阿尔茨海默病状态的准确性、敏感性和特异性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Alzheimer's disease (AD) pathology is thought to progress from normal cognition through preclinical disease and ultimately to symptomatic AD with cognitive impairment. Recent work suggests that the gut microbiome of symptomatic patients with AD has an altered taxonomic composition compared with that of healthy, cognitively normal control individuals. However, knowledge about changes in the gut microbiome before the onset of symptomatic AD is limited. In this cross-sectional study that accounted for clinical covariates and dietary intake, we compared the taxonomic composition and gut microbial function in a cohort of 164 cognitively normal individuals, 49 of whom showed biomarker evidence of early preclinical AD. Gut microbial taxonomic profiles of individuals with preclinical AD were distinct from those of individuals without evidence of preclinical AD. The change in gut microbiome composition correlated with β-amyloid (Aβ) and tau pathological biomarkers but not with biomarkers of neurodegeneration, suggesting that the gut microbiome may change early in the disease process. We identified specific gut bacterial taxa associated with preclinical AD. Inclusion of these microbiome features improved the accuracy, sensitivity, and specificity of machine learning classifiers for predicting preclinical AD status when tested on a subset of the cohort (65 of the 164 participants). Gut microbiome correlates of preclinical AD neuropathology may improve our understanding of AD etiology and may help to identify gut-derived markers of AD risk.
引用
- Ferreiro AL, Choi J, Ryou J, et al. Gut microbiome composition may be an indicator of preclinical Alzheimer's disease. Sci Transl Med. 2023. PMID: 37315112. doi:10.1126/scitranslmed.abo2984
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。